Cited by 273Inflammasome and immune disordersAcute Myeloid Leukemia ResearchBlood disorders and treatments

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

Open access

Sallman, David A., List, Alan·2019·Blood

DOI 10.1182/blood-2018-10-844654PMC PMC7022316

Open this paper in CoChat — free account Open PDF

Abstract

In cancer biology, tumor-promoting inflammation and an inflammatory microenvironment play a vital role in disease pathogenesis. In the past decade, aberrant innate immune activation and proinflammatory signaling within the malignant clone and the bone marrow (BM) microenvironment were identified as key pathogenic drivers of myelodysplastic syndromes (MDS). In particular, S100A9-mediated NOD-like receptor protein 3 (NLRP3) inflammasome activation directs an inflammatory, lytic form of cell death termed pyroptosis that underlies many of the hallmark features of the disease. This circuit and accompanying release of other danger-associated molecular patterns expands BM myeloid-derived suppressor cells, creating a feed-forward process propagating inflammasome activation. Furthermore, somatic gene mutations of varied functional classes license the NLRP3 inflammasome to generate a common phenotype with excess reactive oxygen species generation, Wnt/β-catenin-induced proliferation, cation flux-induced cell swelling, and caspase-1 activation. Recent investigations have shown that activation of the NLRP3 inflammasome complex has more broad-reaching importance, particularly as a possible disease-specific biomarker for MDS, and, mechanistically, as a driver of cardiovascular morbidity/mortality in individuals with age-related, clonal hematopoiesis. Recognition of the mechanistic role of aberrant innate immune activation in MDS provides a new perspective for therapeutic development that could usher in a novel class of disease-modifying agents.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2018-10-844654

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses
Taganov, K. D., Boldin, M. P., Chang, K.-J., & Baltimore, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605298103 · Cited by 4,317
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. M. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,166
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Pyroptosis: host cell death and inflammation
Bergsbaken, T., Fink, S. L., & Cookson, B. T. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2070 · Cited by 3,288
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,224
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202

Show all 81 references

Sorted by citations

Items 101–200 of 273

Advances and challenges in the treatment of myelodysplastic syndromes
Thalla, R., Mack, R. M., Kosti, J., Breslin, P., & Zhang, J. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00678-9 · Cited by 11
Exposure to microbial products followed by loss of Tet2 promotes myelodysplastic syndrome via remodeling HSCs
Yokomizo‐Nakano, T., Hamashima, A., Kubota, S., Bai, J., Sorin, S., Sun, Y., Kikuchi, K., Iimori, M., Morii, M., Kanai, A., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20220962 · Cited by 12
Bone marrow microenvironment in myelodysplastic neoplasms: insights into pathogenesis, biomarkers, and therapeutic targets
Bahmani, F., Shayanmanesh, M., Safari, M., Alaei, A., Pouriafar, Y., Rasti, Z., Zaker, F., Rostami, S., Damerchiloo, F., & Safa, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03793-z · Cited by 12
The Yin and Yang of myelodysplastic syndromes and autoimmunity: The paradox of autoimmune disorders responding to therapies specific for MDS
Fozza, C., Nasa, G. L., & Caocci, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.07.018 · Cited by 11
Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre
Huang, H., Xu, Z., Gao, J., Li, B., Qin, T., Xu, Z., Ren, S., Zhang, Y., Jiao, M., Qu, S., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00349-4 · Cited by 11
Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome
Huang, Y., Wang, Y., Yu, F., Mao, X., Wang, B., Li, J., & Li, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894464 · Cited by 11
Role of the bone marrow immune microenvironment in chronic myelomonocytic leukemia pathogenesis: novel mechanisms and insights into clonal propagation
Mangaonkar, A. A., & Patnaik, M. M. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2056175 · Cited by 11
Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases
Jachiet, V., Ricard, L., Hirsch, P., Malard, F., Pascal, L. B., Beyne‐Rauzy, O., Péterlin, P., Maria, A. T. J., Vey, N., D’Aveni, M., et al. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00866-5 · Cited by 11
Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia
Qiao, W., Young, E. J., Chun, F., Liu, S., Jin, J., Noor, L. Z., Hernandez, C. M. R., Borthakur, G. M., Gorlova, O. Y., & Afshar‐Kharghan, V. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00309-7 · Cited by 12
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?
Bewersdorf, J. P., & Zeidan, A. M. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1819233 · Cited by 11
Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
Kapoor, S., Champion, G., Basu, A., Mariampillai, A., & Olnes, M. J. (2021) · Cancers · doi:10.3390/cancers13195026 · Cited by 11
Is 6-Shogaol an Effective Phytochemical for Patients With Lower-risk Myelodysplastic Syndrome? A Narrative Review
Ooi, S. L., Campbell, R., Pak, S. C., Golombick, T., Manoharan, A., Ramakrishna, R., Badmaev, V., & Schloss, J. M. (2021) · Integrative Cancer Therapies · doi:10.1177/15347354211065038 · Cited by 11
Bone marrow CD3 + CD56 + regulatory T lymphocytes ( TR3 −56 cells) are inversely associated with activation and expansion of bone marrow cytotoxic T cells in IPSS‐R very‐low/low risk MDS patients
Leone, S., Rubino, V., Palatucci, A. T., Giovazzino, A., Carriero, F., Cerciello, G., Pane, F., Ruggiero, G., & Terrazzano, G. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13822 · Cited by 11
Expanding use of CD33-directed immunotherapy
Walter, R. B. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1788540 · Cited by 11
Programmed necroptosis is upregulated in low-grade myelodysplastic syndromes and may play a role in the pathogenesis
Zou, J., Shi, Q., Chen, H., Juskevicius, R., & Zinkel, S. S. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.09.004 · Cited by 10
SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm
Yang, Y., Abbas, S., Sayem, M. A., Dutta, A., & Mohi, G. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00947-y · Cited by 10
Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression
Matsui, S., Ri, C., Bolanos, L. C., Choi, K., Shibamiya, A., Ishii, A., Takaishi, K., Oshima‐Hasegawa, N., Tsukamoto, S., Takeda, Y., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02245-3 · Cited by 10
EGR1 Haploinsufficiency Confers a Fitness Advantage to Hematopoietic Stem Cells Following Chemotherapy
Stoddart, A., Fernald, A. A., Davis, E. M., McNerney, M. E., & Beau, M. M. L. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.08.003 · Cited by 11
Concurrent Zrsr2 mutation and Tet2 loss promote myelodysplastic neoplasm in mice
García-Ruiz, C., Martínez-Valiente, C., Cordón, L., Liquori, A., Fernández‐González, R., Pericuesta, E., Sandoval, J., Cervera, J., Gutiérrez‐Adán, A., & Sanjuán-Pla, A. (2022) · Leukemia · doi:10.1038/s41375-022-01674-2 · Cited by 10
Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
Vaxevanis, C., Bauer, M., Subbarayan, K., Friedrich, M., Massa, C., Biehl, K., Al‐Ali, H. K., Wickenhauser, C., & Seliger, B. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2152998 · Cited by 10
Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes
Schmitt, N., Jann, J.-C., Altrock, E., Flach, J., Danner, J., Uhlig, S., Streuer, A., Knaflic, A., Riabov, V., Xu, Q., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01327-w · Cited by 10
From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review
Comont, T., Treiner, E., & Vergez, F. (2021) · Diagnostics · doi:10.3390/diagnostics11111982 · Cited by 10
Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes
Přibyl, M., Hubáčková, S., Moudrá, A., Vančurová, M., Polackova, H., Stopka, T., Jonasova, A. T., Bokorová, R., Fuchs, O., Stritesky, J., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12768 · Cited by 10
Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications
Simoni, Y., & Chapuis, N. (2022) · Diagnostics · doi:10.3390/diagnostics12071659 · Cited by 9
Inflammatory signaling in the pathogenesis of acute myeloid leukemia
Baumann, A., & Ellegast, J. M. (2025) · HemaSphere · doi:10.1002/hem3.70188 · Cited by 9
EnvIRONmental Aspects in Myelodysplastic Syndrome
Petzer, V., Theurl, I., Weiß, G., & Wolf, D. G. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105202 · Cited by 10
Increased serum C-reactive protein is an adverse prognostic factor in low-risk myelodysplastic syndromes
Baba, Y., Saito, B., Shimada, S., Sasaki, Y., Fujiwara, S., Arai, N., Kawaguchi, Y., Kabasawa, N., Tsukamoto, H., Uto, Y., et al. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03187-7 · Cited by 10
Diagnostic and Prognostic Implications of Caspase-1 and PD-L1 Co-Expression Patterns in Myelodysplastic Syndromes
Graf, J. R., Forster, S., Bruehl, F. K., Banz, Y., Hallal, M., Brodard, J., Bacher, U., Allam, R., Schürch, C. M., & Bonadies, N. (2021) · Cancers · doi:10.3390/cancers13225712 · Cited by 9
Steatotic liver disease in the context of hematological malignancies and anti-neoplastic chemotherapy
Pontikoglou, C. G., Filippatos, T. D., Matheakakis, A., & Papadaki, H. Α. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156000 · Cited by 9
A machine learning-driven framework integrating cell death and senescence signatures for multi-target drug design and immunotherapy optimization in ovarian cancer
Yu, G., Yuan, Q., Sun, Z., Jiang, Z., Feng, X., & Niu, M. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01448-4 · Cited by 10
TLR7 ligation augments hematopoiesis in Rps14 (uS11) deficiency via paradoxical suppression of inflammatory signaling
Peña, O. A., Lubin, A., Rowell, J., Hockings, C., Jung, Y., Hoade, Y., Dace, P., Valdivia, L. E., Tuschl, K., Böiers, C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003055 · Cited by 8
CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients
Uckun, F. M., & Watts, J. M. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.757276 · Cited by 7
Circulating HMGB1 is increased in myelodysplastic syndrome but not in other bone marrow failure syndromes: proof-of-concept cross-sectional study
Apodaca, E., Demichelis‐Gómez, R., Rosas‐López, A., Mejía‐Domínguez, N. R., Galvan-López, I., Addorosio, M., Tracey, K. J., & Valdés‐Ferrer, S. I. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221125990 · Cited by 7
Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
Lucero, J. A., Al-Harbi, S., & Yee, K. W. L. (2023) · Current Oncology · doi:10.3390/curroncol30070459 · Cited by 7
Integrated analysis on mRNA microarray and microRNA microarray to screen immune-related biomarkers and pathways in myelodysplastic syndrome
Lyu, C., Liu, K., Jiang, Y., Wang, T., Wang, Y., & Xu, R. (2021) · Hematology · doi:10.1080/16078454.2021.1938429 · Cited by 7
Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis
de Matos, A. G., Magalhães, S. M. M., & Rauh, M. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_608 · Cited by 7
Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin
Wang, C., McGraw, K. L., McLemore, A. F., Komrokji, R. S., Basiorka, A. A., Ali, N. E. A., Lancet, J. E., Padron, E., Kosmider, O., Fontenay, M., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278855 · Cited by 7
Immune signatures of bone marrow cells can independently predict prognosis in patients with myelodysplastic syndrome
Wang, Y., Lin, C., Yao, C., Hsu, C., Tsai, C., Hou, H., Chou, W., & Tien, H. (2021) · British Journal of Haematology · doi:10.1111/bjh.17837 · Cited by 7
Leukemia core transcriptional circuitry is a sparsely interconnected hierarchy stabilized by incoherent feed-forward loopsPreprint
Harada, T., Kalfon, J., Perez, M. W., Eagle, K., Braes, F. D., Batley, R., Heshmati, Y., Xavier-Ferrucio, J. M., Ewers, J., Mehta, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.13.532438 · Cited by 7
Construction and experimental validation of a novel ferroptosis‐related gene signature for myelodysplastic syndromes
Zhu, Y., He, J., Wei, R., & Liu, J. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1221 · Cited by 6
Effects of immune cells in mediating the relationship between gut microbiota and myelodysplastic syndrome: a bidirectional two-sample, two-step Mendelian randomization study
Feng, Z., Liao, M., Guo, X., Li, L., & Zhang, L. (2024) · Discover Oncology · doi:10.1007/s12672-024-01061-6 · Cited by 6
The Role of NLRP3, a Star of Excellence in Myeloproliferative Neoplasms
Parciante, E., Cumbo, C., Anelli, L., Zagaria, A., Redavid, I., Minervini, A., Conserva, M. R., Tota, G., Coccaro, N., Tarantini, F., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054860 · Cited by 6
Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML
Bauer, M., Jaekel, N., Wilfer, A., Haak, A., Eszlinger, M., Kelemen, K., Hämmerle, M., Al‐Ali, H. K., Seliger, B., & Wickenhauser, C. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2323212 · Cited by 6
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions
Bidikian, A., Bewersdorf, J. P., Shallis, R. M., Getz, T. M., Stempel, J. M., Kewan, T. Z., Stahl, M. F., & Zeidan, A. M. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2414071 · Cited by 6
Pediatric myelodysplastic syndrome with inflammatory manifestations: Diagnosis, genetics, treatment, and outcome
Yanir, A. D., Krauss, A. C., Stein, J., Steinberg‐Shemer, O., Gilad, O., Noy‐Lotan, S., Dgany, O., Krasnov, T., Kodman, Y., Feuerstein, T., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29138 · Cited by 6
Association of systemic inflammatory and autoimmune manifestations with myelodysplastic syndromes: A systematic review and meta-analysis
Liang, Q., Zhao, J., Zhang, L., Gao, Z., Pan, H., Fang, L., & Shi, J. (2022) · Medicine · doi:10.1097/md.0000000000031427 · Cited by 6
Modulating the immune system as a therapeutic target for myelodysplastic syndromes and acute myeloid leukemia
Putnam, C., Kondeti, L., Kesler, M. B. A., & Varney, M. E. (2023) · Biochemistry and Cell Biology · doi:10.1139/bcb-2022-0374 · Cited by 6
Diagnostic and prognostic value of ferroptosis-related genes in patients with Myelodysplastic neoplasms
Chen, X., Li, C., Wang, Y., Geng, S., Xiao, M., Zeng, L., Deng, C., Li, M., Huang, X., Weng, J., et al. (2023) · Hematology · doi:10.1080/16078454.2023.2288475 · Cited by 6
Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression
Casalin, I., Stefano, A. D., Ceneri, E., Cappellini, A., Finelli, C., Curti, A., Paolini, S., Parisi, S., Zannoni, L., Boultwood, J., et al. (2024) · Advances in Biological Regulation · doi:10.1016/j.jbior.2024.101014 · Cited by 6
Toll-Like Receptor 4, 2, and Interleukin 1 Receptor Associated Kinase4: Possible Diagnostic Biomarkers in Myelodysplastic Syndrome Patients
Khalilian, P., Eskandari, N., Sharifi, M. J., Soltani, M., & Nematollahi, P. (2024) · Advanced Biomedical Research · doi:10.4103/abr.abr_67_23 · Cited by 6
The origin of leukemia: Genetic alterations and inflammatory factors in the development of premalignant clonal hematopoiesis
Sjövall, D., & Staffas, A. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.05.003 · Cited by 6
Where There’s Smoke, There’s Fire: Inflammation Drives MDS
Datar, G. K., & Goodell, M. A. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.05.007 · Cited by 8
Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes
Aluri, S., Ling, T., Fraint, E., Chakraborty, S., Zhang, K. X., Ahsan, A., Kravets, L., Poigaialwar, G., Zhao, R., Pradhan, K., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci189266 · Cited by 5
Advances in myelodysplastic syndromes: promising novel agents and combination strategies
Madanat, Y. F., Xie, Z., & Zeidan, A. M. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2166923 · Cited by 5
The Role of Caspase-11 and Pyroptosis in the Regulation of Inflammation in Peri-Implantitis
Jiao, P., Li, Z., Li, B., & Jiao, X. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s427523 · Cited by 5
Beyond HMAs: Novel Targets and Therapeutic Approaches
Getz, T. M., Bewersdorf, J. P., Kewan, T. Z., Stempel, J. M., Bidikian, A., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.08.001 · Cited by 5
Immune‐dysregulation harnessing in myeloid neoplasms
Sharifi, M. J., Xu, L., Nasiri, N., Ashja‐Arvan, M., Soleimanzadeh, H., & Ganjalıkhani-Hakemi, M. (2024) · Cancer Medicine · doi:10.1002/cam4.70152 · Cited by 5
Emerging immuno-oncology targets in Myelodysplastic Syndromes (MDS)
Mann, M., & Brunner, A. M. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100824 · Cited by 5
Why Single-Cell Sequencing Has Promise in MDS
Zhang, X., & Grimes, H. L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769753 · Cited by 5
Increased Circulating of CD54highCD181low Neutrophils in Myelodysplastic Syndrome
Yang, L., Li, H., Liu, Y., Xie, X., Zhang, H.-Q., Niu, H., Shao, Z., Xing, L., & Wang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.585216 · Cited by 4
Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities
Vukotić, M., Kapor, S., Simón, F., Čokić, V. P., & Santibanez, J. F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25081 · Cited by 4
Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects
Li, X., Zou, C., Xiang, X., Zhao, L., Chen, M., Yang, C., & Wu, Y. (2025) · Biomolecules · doi:10.3390/biom15060761 · Cited by 5
Role of Toll‐Like Receptors in Myeloid Neoplasms: Focuses on the Molecular Mechanisms and Clinical Impact on Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myeloid Leukemia
Cavalcante, C. B. A., Chaves, A. C., de Oliveira, V. S., de Araújo, M. A. S., Silva, T. M., Goes, J. V. C., de Oliveira, R. T. G., Pinheiro, R. F., & Ribeiro, H. L. (2025) · Apmis · doi:10.1111/apm.70065 · Cited by 4
Targeting IL-1/IRAK1/4 signaling in acute myeloid leukemia stem cells following treatment and relapse
Ho, T., LaMere, M. W., Kawano, H., Byun, D. K., LaMere, E. A., Chiu, Y., Chen, C., Wang, L., Wang, J., Ramdas, B., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02816-y · Cited by 4
Recipient factors influencing red blood cell alloimmunization
Hendrickson, J. E. (2019) · ISBT Science Series · doi:10.1111/voxs.12485 · Cited by 4
Decitabine Induces Change of Biological Traits in Myelodysplastic Syndromes via FOXO1 Activation
Zhang, Z., Jia, Y., Xv, F., Song, L., Shi, L., Guo, J., & Chang, C. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.603956 · Cited by 4
Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS)
Chee, L. C. Y., Ritchie, D., Ludford‐Menting, M., Ripley, J., Chung, J., Park, D. J., Norton, S., Kenealy, M. K., & Koldej, R. M. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13742 · Cited by 4
Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes
Wang, C., & Sallman, D. A. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01062-7 · Cited by 4
Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders
Hayashi, Y., & Harada, H. (2023) · Cancer Science · doi:10.1111/cas.15810 · Cited by 3
Multi-Walled Carbon Nanotubes Accelerate Leukaemia Development in a Mouse Model
Wang, Q., Han, J., Wei, M., Miao, H., Zhang, M., Wu, B., Chen, Y., Zheng, Y., Gale, R. P., & Yin, B. (2024) · Toxics · doi:10.3390/toxics12090646 · Cited by 5
Increased expression of miR-22 corresponds to the high-risk subtypes of myelodysplastic syndromes and lower OS rate
Ma, Y., Qiao, T., & Meng, Y. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1734591 · Cited by 4
The role of innate immunity in MDS pathogenesis
Sallman, D. A., & List, A. F. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000217 · Cited by 4
Research progress on ferroptosis in Myelodysplastic syndromes
Yang, Y., Han, J., Wei, Y., Jin, J., & Feng, W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1561072 · Cited by 3
Analysis of the Correlation Between MDS Inflammatory Indicators and Clinical Characteristics: A Comprehensive Analysis
Hu, Z., Pei, L., Hu, Z., Yang, Y., Wang, Y., Hua, M., & Zhao, P. (2025) · Mediators of Inflammation · doi:10.1155/mi/8812329 · Cited by 3
Deep learning-based morphological assessment of myelodysplastic syndrome on bone marrow smears
Kaji, S., Kawai, H., Shimbo, K., Maeda, T., Matsuda, A., & Mori, J. (2025) · Leukemia Research · doi:10.1016/j.leukres.2025.107923 · Cited by 3
Increased CXCL10 (IP-10) is associated with advanced myeloproliferative neoplasms and its loss dampens erythrocytosis in mouse models
Belmonte, M., Cabrera-Cosme, L., Øbro, N. F., Li, J., Grinfeld, J., Milek, J., Bennett, E., Irvine, M., Shepherd, M. S., Cull, A. H., et al. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104246 · Cited by 4
The diagnostic value and clinical correlations of bone marrow supernatant S100A8 and S100A9 in myelodysplastic neoplasms
Li, X., Li, Q. Y., Xiang, X., Zhang, X., & Wu, Y. (2025) · Cytokine · doi:10.1016/j.cyto.2025.156856 · Cited by 5
Low‐risk MDS—A spotlight on precision medicine for SF3B1‐mutated patients
Burke, S., Chowdhury, O., & Rouault‐Pierre, K. (2025) · HemaSphere · doi:10.1002/hem3.70103 · Cited by 4
A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms
Wu, J., Liu, J., Chen, J., Yang, L., Li, F., Qin, T., Xu, Z., Liu, J., Zhou, J., Shi, L., et al. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00664-1 · Cited by 3
SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes
Volpe, V. O., Garcia‐Manero, G., & Komrokji, R. S. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.01.001 · Cited by 3
Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment
Bewersdorf, J. P., Xie, Z., & Zeidan, A. M. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000658 · Cited by 3
Pathogen and human NDPK-proteins promote AML cell survival via monocyte NLRP3-inflammasome activation
Trova, S., Lin, F., Lomada, S. K., Fenton, M., Chauhan, B., Adams, A., Puri, A., Maio, A. D., Wieland, T., Sewell, D., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288162 · Cited by 3
Thymocyte selection‐associated high mobility box protein regulates T lymphocytes exhaustion in patients with myelodysplastic syndromes by inhibiting PI3K/AKT/mTOR pathway
Niu, H., Zhang, M., Liu, M., Yang, L., Yang, L., Ren, J., Yu, Y., Liu, Y., Xing, L., Shao, Z., et al. (2023) · Hematological Oncology · doi:10.1002/hon.3224 · Cited by 3
TNFα induces Caspase-3 activity in hematopoietic progenitor cells CD34+, CD33+, and CD41 + of myelodysplastic syndromes
Iriani, A., Rachman, A., Setiabudy, R. D., Kresno, S. B., Sudoyo, A. W., Arief, M., Harahap, A. R., & Fatina, M. K. (2023) · BMC Molecular and Cell Biology · doi:10.1186/s12860-023-00495-0 · Cited by 3
Hematologic Disorders
Grant, S. J., & Jiang, D. C. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_53 · Cited by 3
A pyroptosis-related gene expression signature predicts immune microenvironment and prognosis in head and neck squamous cell carcinoma
Zhou, W., Feng, M., Qi, F., Qiao, J., Fan, L., Zhang, L., Hu, X., & Huang, C. (2023) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-023-08316-y · Cited by 2
Characterization of the Molecular Signature of Human Monocytes in Aging and Myelodysplastic Neoplasms
Rimpa, C. M., Grigoriou, M., Tasis, A., Paschalidis, N., Filia, A., Vatsellas, G., Papazoglou, P., Chatzigeorgiou, A., Kymparidou, C., Papoutselis, M. K., et al. (2024) · European Journal of Immunology · doi:10.1002/eji.202451387 · Cited by 2
Improving MDS Risk Assessment: The Role of Monocytopenia and Lymphocytopenia Beyond IPSS-R
Virijević, M., Jakovic, L. R., Trajković, L., Cvetković, M., Pravdić, Z., Mitrović, M., Suvajdžić, N., & Bogdanovic, A. D. (2025) · Medicina · doi:10.3390/medicina61091689 · Cited by 2
Chromatin accessibility in stem cells unveils progressive transcriptional alterations in myelodysplastic syndrome
Oshima, M., Takayama, N., Nakajima-Takagi, Y., Shinoda, D., Itokawa, N., Kurosawa, S., Kaito, S., Kamiya, T., Yamada, Y., Andoh, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65753-5 · Cited by 2
Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia
Uible, E. E., Choi, I., Clough, C. A., Hassan, A., Anandappa, A. J., Fisher, J., Karki, B., Hueneman, K. M., Choi, K., Vick, E. J., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2025.12.002 · Cited by 2
Functions of mitochondrial metabolism in hematopoiesis and hematopoietic malignancies
Yi, S., Zhang, H., & Sheng, Y. (2026) · Blood Science · doi:10.1097/bs9.0000000000000271 · Cited by 2
Time-Dependent Prognostic Value of the mEASIX Score in Patients with Myelodysplastic Syndromes
Yanık, A. M., Sadri, S., Şan, A. B., Gül, Ö. Ö., Koca, T. G., Hunutlu, F. Ç., Bilen, Y., Gürsoy, V., Özkocaman, V., & Özkalemkaş, F. (2026) · Diagnostics · doi:10.3390/diagnostics16111640 · Cited by 2
Fanca deficiency is associated with alterations in osteoclastogenesis that are rescued by TNFα
Oppezzo, A., Monney, L., Kilian, H., Slimani, L., Maczkowiak, F., & Rosselli, F. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01067-7 · Cited by 2
Clonal evolution in leukemia: preleukemia, evolutionary models, and clinical implications
He, X., Xia, M.-F., Teng, J.-Y., Zhou, B. S., & Wang, Q. (2023) · Genome Instability & Disease · doi:10.1007/s42764-023-00104-6 · Cited by 3
Hematologic Disorders
Grant, S. J., & Jiang, D. C. (2023) · Springer eBooks · doi:10.1007/978-3-030-01782-8_53-1 · Cited by 2
Myelodysplastic Syndrome
Fuchs, O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00046-9 · Cited by 2
The different faces of GATA2 deficiency: implications for therapy and surveillance
Vinci, L., Strahm, B., Speckmann, C., & Erlacher, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1423856 · Cited by 2
Pediatric Myelodysplastic Syndrome: Updated Classifications and Current Diagnosis and Treatment Challenges
Inam, Z. S., Pan, M., Diab, Y., Schore, R. J., Vatsayan, A., & Cheng, J. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2024-0164-ra · Cited by 3
Preclinical efficacy of tasquinimod in myelodysplastic neoplasms: Restoring erythropoiesis and mitigating bone loss
Wobus, M., Weidner, H., Wehner, R., Baumann, A.-L., Möbus, K., Balaian, E., Törngren, M., Vahtola, E., Eriksson, H., Winter, S., et al. (2026) · HemaSphere · doi:10.1002/hem3.70352 · Cited by 2
Case Study: Are Low Concentrations of Benzene Disproportionately Dangerous?
Cox, L. A. (2020) · International series in management science/operations research/International series in operations research & management science · doi:10.1007/978-3-030-57358-4_12 · Cited by 2

Authors: Sallman, D. A., & List, A.
Affiliations: Moffitt Cancer Center (US)
ORCID: Sallman, David A.
List, Alan
Venue: Blood
Publisher: American Society of Hematology
Published: 2019-03-07
Volume: 133
Issue: 10
Pages: 1039-1048
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2018-10-844654
PMC: PMC7022316
OpenAlex: W2913296480
Cited by: 273
References: 81
Citations by year: 2026: 26 · 2025: 27 · 2024: 39 · 2023: 47 · 2022: 38 · 2021: 59 · 2020: 23 · 2019: 14
FWCI: 2.96
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P30CA076292)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Hematology › Blood disorders and treatments
Keywords: myelodysplastic syndrome, NLRP3 inflammasome, S100A9, pyroptosis, bone marrow microenvironment, myeloid-derived suppressor cells, innate immune activation, clonal hematopoiesis, cardiovascular morbidity, caspase-1, reactive oxygen species, Wnt/β-catenin signaling, disease biomarkers, disease-modifying therapy
MeSH terms: Pyroptosis, NLR Family, Pyrin Domain-Containing 3 Protein, Bone Marrow, Bone Marrow Cells, Hematopoiesis, Humans, Immunity, Innate, Inflammation, Mutation, Myelodysplastic Syndromes, Phenotype, Signal Transduction, Reactive Oxygen Species, Inflammasomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks